Advertisement

Journal of Gastrointestinal Surgery

, Volume 23, Issue 1, pp 93–100 | Cite as

Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation

  • Andrea Ruzzenente
  • Fabio Bagante
  • Francesca Bertuzzo
  • Luca Aldrighetti
  • Tommaso Campagnaro
  • Giorgio Ercolani
  • Simone Conci
  • Felice Giuliante
  • Andrea Dore
  • Alessandro Ferrero
  • Guido Torzilli
  • Gian Luca Grazi
  • Francesca Ratti
  • Alessandro Cucchetti
  • Agostino M. De Rose
  • Nadia Russolillo
  • Matteo Cimino
  • Pasquale Perri
  • Alfredo Guglielmi
  • Calogero IaconoEmail author
2018 SSAT Plenary Presentation

Abstract

Background

The role of liver transplant (LT) for neuroendocrine liver metastasis (NELM) has not been completely defined. While international guidelines included LT as a potential treatment for highly selected patients with advanced NELM, recently, LT has been proposed as an alternative curative treatment for NELM for patients meeting restrictive criteria (Milan criteria).

Methods

Using a multi-institutional cohort of patients undergoing liver resection for NELM, the long-term outcomes of patients meeting Milan criteria (resected NET drained by the portal system, stable disease/response to therapies for at least 6 months, metastatic diffusion to < 50% of the total liver volume, a confirmed histology of low-grade, and ≤ 60 years) were investigated.

Results

Among the 238 patients included in the study, 28 (12%) patients met the Milan criteria for LT with a 5-year OS of 83%. Furthermore, among patients meeting Milan criteria, subsets of patients with favorable clinic-pathological characteristics had 5-year OS rates greater than 90% including G1 patients (5-year OS, 92%), patients undergoing minor liver resection (5-year OS, 94%), patients with low number of NELM (1–2 NELM), and small tumor size (< 3 cm) (for both groups of patients, 5-year OS, 100%).

Conclusions

In our series, only 12% of patients met Milan criteria, and the 5-year OS after liver resection for this small selected group of patients was comparable with that reported in the literature for patients undergoing LT for NELM within Milan criteria. While LT might be the optimal treatment for patients with unresectable NELM, surgical resection should be the first option for patients with resectable NELM.

Keywords

Neuroendocrine liver metastasis Liver surgery Liver transplant 

Notes

Acknowledgements

The work of Dr. Francesca Bertuzzo was supported by the Fondo Unico per la Ricerca (FUR) 2017 and the Fondazione Livia and Vittorio Tonolli, Verbania, Italy.

Authors’ Contribution

- Design of the work: all authors.

- Analysis and interpretation of data for the work: C. Iacono, A. Ruzzenente, and F. Bagante.

- Drafting the work: C. Iacono, A. Ruzzenente, F. Bagante.

- Revising it critically for important intellectual content: all authors.

- Final approval of the version to be published: all authors.

- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: all authors.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–12.  https://doi.org/10.1097/MPA.0b013e3181ec124e.CrossRefPubMedGoogle Scholar
  2. 2.
    Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(18):3063–72.  https://doi.org/10.1200/JCO.2007.15.4377.CrossRefGoogle Scholar
  3. 3.
    Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21(9):1794–803.  https://doi.org/10.1093/annonc/mdq022.CrossRefGoogle Scholar
  4. 4.
    Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinology and metabolism clinics of North America. 2011;40(1):1–18, vii.  https://doi.org/10.1016/j.ecl.2010.12.005.CrossRefPubMedGoogle Scholar
  5. 5.
    Chan MY, Ma KW, Chan A. Surgical management of neuroendocrine tumor-associated liver metastases: a review. Gland Surg. 2018;7(1):28–35.  https://doi.org/10.21037/gs.2017.11.16.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ruzzenente A, Bagante F, Bertuzzo F, Aldrighetti L, Ercolani G, Giuliante F et al. A Novel Nomogram to Predict the Prognosis of Patients Undergoing Liver Resection for Neuroendocrine Liver Metastasis: an Analysis of the Italian Neuroendocrine Liver Metastasis Database. J Gastrointest Surg. 2017;21(1):41–8.  https://doi.org/10.1007/s11605-016-3228-6.CrossRefPubMedGoogle Scholar
  7. 7.
    Spolverato G, Bagante F, Aldrighetti L, Poultsides G, Bauer TW, Field RC et al. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. J Gastrointest Surg. 2017;21(12):2039–47.  https://doi.org/10.1007/s11605-017-3491-1.CrossRefPubMedGoogle Scholar
  8. 8.
    Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–97.  https://doi.org/10.1002/cncr.29099.CrossRefPubMedGoogle Scholar
  9. 9.
    Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50(1):58–64.  https://doi.org/10.1007/s00535-014-0934-2.CrossRefPubMedGoogle Scholar
  10. 10.
    Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surgical oncology. 2012;21(3):e131–41.  https://doi.org/10.1016/j.suronc.2012.05.001.CrossRefPubMedGoogle Scholar
  11. 11.
    Alagusundaramoorthy SS, Gedaly R. Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World J Gastroenterol. 2014;20(39):14348–58.  https://doi.org/10.3748/wjg.v20.i39.14348.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Mazzaferro V, Sposito C, Coppa J, Miceli R, Bhoori S, Bongini M et al. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. Am J Transplant. 2016;16(10):2892–902.  https://doi.org/10.1111/ajt.13831.CrossRefPubMedGoogle Scholar
  13. 13.
    Ravaioli M, Ercolani G, Neri F, Cescon M, Stacchini G, Del Gaudio M et al. Liver transplantation for hepatic tumors: a systematic review. World J Gastroenterol. 2014;20(18):5345–52.  https://doi.org/10.3748/wjg.v20.i18.5345.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Fan ST, Le Treut YP, Mazzaferro V, Burroughs AK, Olausson M, Breitenstein S et al. Liver transplantation for neuroendocrine tumour liver metastases. HPB (Oxford). 2015;17(1):23–8.  https://doi.org/10.1111/hpb.12308.CrossRefPubMedGoogle Scholar
  15. 15.
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.  https://doi.org/10.1056/NEJM199603143341104.CrossRefPubMedGoogle Scholar
  16. 16.
    Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47(4):460–6.  https://doi.org/10.1016/j.jhep.2007.07.004.CrossRefPubMedGoogle Scholar
  17. 17.
    Coppa J, Pulvirenti A, Schiavo M, Romito R, Collini P, Di Bartolomeo M et al. Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplant Proc. 2001;33(1–2):1537–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. World Health Organization classification of tumours, vol 3. Lyon: International Agency for Research on Cancer; 2010.Google Scholar
  19. 19.
    Belgihiti J CP, , Gadzijev, et al. . The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000;2:333–9.CrossRefGoogle Scholar
  20. 20.
    Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96(2):175–84.  https://doi.org/10.1002/bjs.6468.CrossRefPubMedGoogle Scholar
  21. 21.
    R Core Development Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2015.Google Scholar
  22. 22.
    Therneau TM, Grambsch PM. Modeling survival data : extending the Cox model. Statistics for biology and health. New York: Springer; 2000.CrossRefGoogle Scholar
  23. 23.
    Frank E Harrell Jr with contributions from Charles Dupont and many others. Hmisc: Harrell Miscellaneous. 2016. R CRAN package available at https://cran.r-project.org/web/packages/Hmisc/index.html (last accessed on 09/12/2018)
  24. 24.
    Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.  https://doi.org/10.1200/JCO.2009.22.8510.CrossRefPubMedGoogle Scholar
  25. 25.
    Cives M, Strosberg J. Radionuclide Therapy for Neuroendocrine Tumors. Curr Oncol Rep. 2017;19(2):9.  https://doi.org/10.1007/s11912-017-0567-8.CrossRefPubMedGoogle Scholar
  26. 26.
    Kwekkeboom DJ, Krenning EP. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016;30(1):179–91.  https://doi.org/10.1016/j.hoc.2015.09.009.CrossRefPubMedGoogle Scholar
  27. 27.
    Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125–35.  https://doi.org/10.1056/NEJMoa1607427.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.  https://doi.org/10.1056/NEJMoa1316158.CrossRefPubMedGoogle Scholar
  29. 29.
    Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–77.  https://doi.org/10.1016/S0140-6736(15)00817-X.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13.  https://doi.org/10.1056/NEJMoa1003825.CrossRefPubMedGoogle Scholar
  31. 31.
    Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev. 2009(2).  https://doi.org/10.1002/14651858.CD007060.pub2.
  32. 32.
    Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190(4):432–45.CrossRefPubMedGoogle Scholar
  33. 33.
    Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130(4):677–82; discussion 82–5.  https://doi.org/10.1067/msy.2001.117377.CrossRefPubMedGoogle Scholar
  34. 34.
    Mayo SC, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18(13):3657–65.  https://doi.org/10.1245/s10434-011-1832-y.CrossRefPubMedGoogle Scholar
  35. 35.
    Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572–81.  https://doi.org/10.1245/ASO.2006.03.071.CrossRefPubMedGoogle Scholar
  36. 36.
    Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87(1):47–62.  https://doi.org/10.1159/000111037.CrossRefPubMedGoogle Scholar
  37. 37.
    Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172–85.  https://doi.org/10.1159/000443167.CrossRefPubMedGoogle Scholar
  38. 38.
    Gedaly R, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg. 2011;146(8):953–8.  https://doi.org/10.1001/archsurg.2011.186.CrossRefPubMedGoogle Scholar
  39. 39.
    Le Treut YP, Gregoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257(5):807–15.  https://doi.org/10.1097/SLA.0b013e31828ee17c.CrossRefPubMedGoogle Scholar
  40. 40.
    Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76.  https://doi.org/10.1159/000335597.CrossRefPubMedGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2018

Authors and Affiliations

  • Andrea Ruzzenente
    • 1
  • Fabio Bagante
    • 1
  • Francesca Bertuzzo
    • 1
  • Luca Aldrighetti
    • 2
  • Tommaso Campagnaro
    • 1
  • Giorgio Ercolani
    • 3
  • Simone Conci
    • 1
  • Felice Giuliante
    • 4
  • Andrea Dore
    • 1
  • Alessandro Ferrero
    • 5
  • Guido Torzilli
    • 6
  • Gian Luca Grazi
    • 7
  • Francesca Ratti
    • 2
  • Alessandro Cucchetti
    • 3
  • Agostino M. De Rose
    • 4
  • Nadia Russolillo
    • 5
  • Matteo Cimino
    • 6
  • Pasquale Perri
    • 7
  • Alfredo Guglielmi
    • 1
  • Calogero Iacono
    • 1
    • 8
    Email author
  1. 1.General and Hepatobiliary Surgery, Department of Surgery, School of MedicineUniversity of VeronaVeronaItaly
  2. 2.Department of Surgery, School of MedicineOspedale San RaffaeleMilanItaly
  3. 3.Department of Surgery, School of Medicine, Ospedale Sant’OrsolaUniversity of BolognaBolognaItaly
  4. 4.Department of Surgery, School of MedicineCatholic University of the Sacred HeartRomeItaly
  5. 5.Department of Surgery, School of MedicineOspedale Mauriziano Umberto ITurinItaly
  6. 6.Department of Surgery, School of MedicineIstituto Clinico HumanitasMilanItaly
  7. 7.Department of Surgery, School of MedicineRegina Elena National Cancer InstituteRomeItaly
  8. 8.Department of Surgery and Oncology, Division of General and HPB Surgery, School of MedicineUniversity of VeronaVeronaItaly

Personalised recommendations